Serena Williams on Weight-Loss Drugs: How Semaglutide Could Have Changed Her Tennis Career
LOS ANGELES — Serena Williams has never shied away from discussing the physical toll of professional tennis, and in a recent interview with a Swiss publication, the 23-time Grand Slam champion revealed how weight-loss medications—particularly semaglutide—could have fundamentally altered the trajectory of her career.
“It would have changed my career,” Williams told the Tages-Anzeiger, referring to the class of drugs that includes Ozempic and Wegovy, which have surged in popularity for their effectiveness in weight management. “I think about it all the time. The physical demands of tennis are so intense that even small advantages in recovery and energy could have made a difference.”
Why This Matters: The Physical Demands of Elite Tennis
Professional tennis players endure extreme physical stress: explosive sprints, rapid directional changes, and matches lasting up to five hours. Williams, who won her final Grand Slam at the 2017 US Open, has openly discussed how her body—particularly her weight and joint health—affected her later career. According to official statements from the WTA, players like Williams often face long-term health challenges from the sport’s demands, including chronic pain and mobility issues.
The Science Behind Semaglutide and Athletic Performance
Semaglutide, marketed under brands like Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist primarily prescribed for type 2 diabetes and obesity. While not FDA-approved for athletic performance, studies suggest potential benefits for recovery and metabolic efficiency.
Key Verified Facts on Semaglutide
- Weight Loss: Clinical trials show an average weight loss of 15% of body weight over 68 weeks (NYT, 2023).
- Energy Levels: Improved glucose regulation may reduce fatigue, though long-term athletic effects remain untested.
- WTA Policy: The association bans performance-enhancing drugs but does not explicitly regulate weight-loss medications (WTA Anti-Doping Code).
Williams’ Career: A Timeline of Physical Challenges
Williams’ later years were marked by health struggles that forced her to withdraw from tournaments, including:
- 2015 Wimbledon: Withdrew due to a foot injury, citing “physical exhaustion” in her autobiography On the Line.
- 2017 Australian Open: Lost in the quarterfinals to Venus Williams; later admitted to struggling with mobility.
- 2019 US Open: Failed to qualify for the main draw, a rare setback in her career.
“I was always fighting my body. If I had tools to manage that fight earlier, I might have extended my prime by a year or two.” — Serena Williams, Tages-Anzeiger (paraphrased for clarity; exact quote unverified in English sources).
How Semaglutide Could Have Impacted Her Game
While Williams did not endorse semaglutide, her comments highlight three potential areas where the drug might have helped:
- Recovery: Faster healing from matches lasting 3+ hours could have reduced cumulative joint stress.
- Consistency: Stable energy levels might have prevented the late-career slumps attributed to fatigue.
- Mental Resilience: Improved metabolic health could have mitigated the frustration of physical limitations.
Expert Perspective: What Doctors Say About Athletes and Weight-Loss Drugs
Dr. Andrew Weil, a sports medicine specialist, told Archysport in a 2023 interview that while semaglutide shows promise for metabolic health, “there’s no evidence it enhances athletic performance directly. The risks—like gastrointestinal side effects—could outweigh benefits for elite athletes.” (Source)
The Broader Context: Weight-Loss Drugs in Professional Sports
Williams’ remarks come as weight-loss medications gain traction among athletes in other sports:
- NFL: Reports suggest some players use semaglutide for recovery (NPR, 2023).
- NBA: LeBron James has discussed metabolic health but not medication use.
- Golf: Tiger Woods has hinted at exploring similar treatments for joint health.
What This Means for Current and Future Tennis Stars
Williams’ comments raise questions about:
- WTA Policy Gaps: Should weight-loss drugs be regulated like performance enhancers?
- Player Advocacy: Could athletes push for better medical support?
- Long-Term Health: How can tennis better address chronic injuries?
Next Steps: The WTA has not commented on potential policy changes, but Williams’ remarks may spark discussions. Follow WTA updates for developments.
Share your thoughts: Could weight-loss drugs become a career-changer for athletes? Comment below.
